Compare · IDXX vs ZTS
IDXX vs ZTS
Side-by-side comparison of IDEXX Laboratories Inc. (IDXX) and Zoetis Inc. (ZTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. IDXX focuses on Biotechnology: In Vitro & In Vivo Diagnostic Substances, while ZTS focuses on Biotechnology: Pharmaceutical Preparations.
- IDXX is the larger of the two at $54.33B, about 1.7x ZTS ($32.82B).
- Over the past year, IDXX is up 0.1% and ZTS is down 30.2% - IDXX leads by 30.3 points.
- IDXX has been more active in the news (10 items in the past 4 weeks vs 7 for ZTS).
- Both have 25 recent analyst ratings on file.
- Company
- IDEXX Laboratories Inc.
- Zoetis Inc.
- Price
- $689.78-1.26%
- $80.82-5.56%
- Market cap
- $54.33B
- $32.82B
- 1M return
- +24.65%
- +1.52%
- 1Y return
- +0.06%
- -30.24%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 1991
- 2013
- News (4w)
- 10
- 7
- Recent ratings
- 25
- 25
IDEXX Laboratories Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Zoetis Inc.
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, blood glucose monitors, and laboratory services; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Latest IDXX
- Executive Chair of the Board Jonathan Jay Mazelsky gifted 700 shares, decreasing direct ownership by 0.84% to 83,103 units (SEC Form 4)
- Executive Vice President Fennell George exercised 1,749 shares at a strike of $171.38, increasing direct ownership by 17% to 12,182 units (SEC Form 4)
- EVP, GC & Corporate Secretary Underberg Sharon E. exercised 8,906 shares at a strike of $288.78 and sold $6,132,605 worth of shares (8,906 units at $688.59) (SEC Form 4)
- Executive Vice President Lane Michael sold $2,740,069 worth of shares (3,979 units at $688.64), decreasing direct ownership by 49% to 4,076 units (SEC Form 4)
- Executive Chair of the Board Mazelsky Jonathan Jay exercised 25,140 shares at a strike of $178.26 and sold $17,678,195 worth of shares (25,140 units at $703.19) (SEC Form 4)
- Director Junius Daniel M sold $844,888 worth of shares (1,200 units at $704.07), decreasing direct ownership by 34% to 2,361 units (SEC Form 4)
- Director Hooley Joseph L was granted 48 shares, increasing direct ownership by 15% to 373 units (SEC Form 4)
- SEC Form 10-Q filed by IDEXX Laboratories Inc.
- IDEXX Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- IDEXX Laboratories Announces Third Quarter Results
Latest ZTS
- Zoetis Receives USDA License for Poulvac® Procerta® HVT-ND-ILT Vaccine for Chickens
- Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic Dermatitis
- Zoetis to Participate in the Jefferies Global Healthcare Conference in London
- SEC Form 10-Q filed by Zoetis Inc.
- Zoetis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Zoetis Announces Third Quarter 2026 Results; Highlights Progress Advancing Innovation Across Diversified Portfolio and Narrows Full Year 2026 Revenue Guidance, Raises Full Year 2026 Adjusted EPS Guidance
- Director Stetter Mark was granted 6 phantom stock units (SEC Form 4)
- Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment
- Zoetis downgraded by Jefferies with a new price target
- Goldman initiated coverage on Zoetis with a new price target